Drug safety and tolerability in prophylactic migraine treatment

Expert Opinion on Drug Safety

Volumn 14, Issue 5, 2015, Pages 667-681

  Vécsei, László ^a   Majláth, Zsófia ^a   Szok, Délia ^a   Csáti, Anett ^a   Tajti, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Efficacy; Migraine; Prophylactic treatment; Safety; Tolerability

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CYPROHEPTADINE; FLUNARIZINE; METOPROLOL; PROPRANOLOL; RIZATRIPTAN; TOPIRAMATE; VALPROIC ACID;

ADVERSE DRUG REACTION; ALTERNATIVE MEDICINE; BREAST FEEDING; DEPRESSION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MIGRAINE; MIGRAINE WITHOUT AURA; PREGNANCY; PROPHYLAXIS; REVIEW; TRANSFORMED MIGRAINE; WEIGHT GAIN; ANIMAL; FEMALE; MALE; MIGRAINE DISORDERS; PERSONALIZED MEDICINE; PROCEDURES; QUALITY OF LIFE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTICONVULSANTS; BOTULINUM TOXINS, TYPE A; CALCIUM CHANNEL BLOCKERS; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PRECISION MEDICINE; QUALITY OF LIFE;

EID: 84928311696     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1014797     Document Type: Review

References (137)

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
3. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 1991;44:1147-57
4. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36
5. Steiner TJ, Gururaj G, Andree C, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 2014;15:3
6. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
7. Tfelt-Hansen PC, Pihl T, Hougaard A, Mitsikostas DD. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 2014;23:375-85
8. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-42
9. Waters WE. Community studies of the prevalence of headache. Headache 1970;9:178-86
10. Tajti J, Pardutz A, Vamos E, et al. Migraine is a neuronal disease. J Neural Transm 2011;118:511-24
11. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
12. Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain 2014;137:650-1
13. Andrasik F, Lipchik GL, McCrory DC, Wittrock DA. Outcome measurement in behavioral headache research: headache parameters and psychosocial outcomes. Headache 2005;45:429-37
14. Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 2008;9:2565-73
15. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
16. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45
17. Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87-99
18. Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53:1548-63
19. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
20. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53
21. Chung JY, Kim MW, Kim M. Efficacy of zonisamide in migraineurs with nonresponse to topiramate. Biomed Res Int 2014;2014:891348
22. Jion YI, Raff A, Grosberg BM, Evans RW. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Headache 2015;55:161-6
23. Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med 1991;90:48S-53S
24. Okuma H, Iijima K, Yasuda T, et al. Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine. Springerplus 2013;2:573
25. Pizza V, Busillo V, Agresta A, et al. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011;11:31-4
26. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012;39:S1-59
27. Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India. Clin Neuropharmacol 2013;36:193-7
28. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010608
29. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52:237-43
30. Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 2005;128:86-97
31. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59:652-61
32. Nicholls DP, Harron DW, McAinsh J, et al. Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers. Br J Clin Pharmacol 1982;14:727-32
33. Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-15
34. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979;7:49-54
35. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. Br Med J 1974;2:699-701
36. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984;69:1-8
37. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a doubleblind, placebo-controlled study. Cephalalgia 1989;9:247-53
38. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013;28:1225-37
39. Shiri R, Koskimaki J, Hakkinen J, et al. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007;19:208-12
40. Kostis JB, Rosen RC, Holzer BC, et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990;102:163-70
41. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004;21:377-93
42. Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988;17:241-55
43. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984;4:91-6
44. Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-6
45. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991;32:581-4
46. Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001;52:69-76
47. Peck RW, Seaber EJ, Dixon R, et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol 1997;44:595-9
48. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45
49. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7
50. Perez-Stable EJ, Coates TJ, Baron RB, et al. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med 1995;10:419-28
51. Taylor FR. Weight change associated with the use of migraine-preventive medications. Clin Ther 2008;30:1069-80
52. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 1996;16:328-36; discussion 288
53. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004;CD003225
54. Spahn H, Kirch W, Mutschler E, et al. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br J Clin Pharmacol 1984;17(Suppl 1):97S-102S
55. Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 2013;94:394-9
56. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache 1988;28:15-23
57. Siniatchkin M, Andrasik F, Kropp P, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 2007;27:1024-32
58. Sorensen PS, Larsen BH, Rasmussen MJ, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;31:650-7
59. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001;21:120-8
60. Smelt AF, Assendelft WJ, van Dijk CE, Blom JW. Triptan use after starting prophylactic migraine treatment: a retrospective cohort study in a primary care population. Cephalalgia 2014;34:927-32
61. Quarterman CP, Kendall MJ, Jack DB. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol 1981;11:287-94
62. Agnoli A. The classification of calcium antagonists by the WHO expert committee: relevance in neurology. Cephalalgia 1988;8(Suppl 8):7-10
63. Della Paschoa OE, Hoogerkamp A, Edelbroek PM, et al. Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. Epilepsy Res 2000;40:41-52
64. Holmes B, Brogden RN, Heel RC, et al. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27:6-44
65. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981;21:235-9
66. Mentenopoulos G, Manafi T, Logothetis J, Bostantzopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985;5(Suppl 2):135-40
67. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209-21
68. Lucking CH, Oestreich W, Schmidt R, Soyka D. Flunarizine vs. propranolol in the prophylaxis of migraine: two doubleblind comparative studies in more than 400 patients. Cephalalgia 1988;8(Suppl 8):21-6
69. Luo N, Di W, Zhang A, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012;13:80-6
70. Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005;25:1048-53
71. de Bock GH, Eelhart J, van Marwijk HW, et al. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci 1997;19:269-74
72. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol 1996;51:15-22
73. Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol 2014;7:191-201
74. Chen LC, Chou MH, Lin MF, Yang LL. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther 2000;25:453-9
75. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010611
76. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
77. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-8
78. Shahien R, Beiruti K. Preventive agents for migraine: focus on the antiepileptic drugs. J Cent Nerv Syst Dis 2012;4:37-49
79. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9
80. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015;35:51-62
81. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20
82. Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. Headache 2011;51:554-8
83. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012;11:792-802
84. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010;9:285-98
85. Marmura MJ. Safety of topiramate for treating migraines. Expert Opin Drug Saf 2014;13:1241-7
86. Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013;54:1444-52
87. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27:154-65
88. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73
89. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-75
90. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118:301-5
91. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122:60-8
92. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010610
93. Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol 2011;18:1115-21
94. Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol 2012;25:290-5
95. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
96. Forderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2002;22:186-9
97. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-81
98. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat 2006;2:281-91
99. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85:283-8
100. Etminan M, Maberley D, Mikelberg FS. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol 2012;153:827-30
101. Ho JD, Keller JJ, Tsai CY, et al. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol 2013;155:336-41.e1
102. Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol 1999;48:71-8
103. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17
104. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512
105. Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc 1979;54:669-74
106. Snyder SH, Yamamura HI. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977;34:236-9
107. Couch JR; Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51
108. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9
109. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825-30
110. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-59
111. Gore M, Dukes E, Rowbotham D, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract 2006;6:265-72
112. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240-4
113. Anderson N, Meier T, Borlak J. Toxicogenomics applied to cultures of human hepatocytes enabled an identification of novel petasites hybridus extracts for the treatment of migraine with improved hepatobiliary safety. Toxicol Sci 2009;112:507-20
114. Facco E, Liguori A, Petti F, et al. Acupuncture versus valproic acid in the prophylaxis of migraine without aura: a prospective controlled study. Minerva Anestesiol 2013;79:634-42
115. Hesse J, Mogelvang B, Simonsen H. Acupuncture versus metoprolol in migraine prophylaxis: a randomized trial of trigger point inactivation. J Intern Med 1994;235:451-6
116. Linde K, Allais G, Brinkhaus B, et al. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009;CD001218
117. Aurora SK, Dodick DW, Diener HC, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 2014;129:61-70
118. Tajti J, Szok D, Tuka B, et al. [Botulinum neurotoxin-a therapy in migraine]. Ideggyogy Sz 2012;65:77-82
119. Liberini P, Pari E, Gazzina S, et al. Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm. Neurol Sci 2014;35(Suppl 1):41-3
120. Cernuda-Morollon E, Ramon C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 2014. [Epub ahead of print]
121. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
122. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466-78
123. Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Headache Pain 2013;14:7
124. Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs 2012;26:791-811
125. Savi L, Mogavero S, Egan CG. Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug Des Devel Ther 2014;8:983-92
126. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003;2:123-32
127. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9
128. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-48
129. Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy: options for therapy. CNS Drugs 2005;19:465-81
130. Cassina M, Di Gianantonio E, Toldo I, et al. Migraine therapy during pregnancy and lactation. Expert Opin Drug Saf 2010;9:937-48
131. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol 2014;70:1313-24
132. Hutchinson S, Marmura MJ, Calhoun A, et al. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache 2013;53:614-27
133. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 2001;41(Suppl 1):S18-24
134. Mueller LL. Diagnosing and managing migraine headache. J Am Osteopath Assoc 2007;107:ES10-16
135. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012;29:613-24
136. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014;20:22-33
137. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014;28:389-99